Conţinutul numărului revistei |
Articolul precedent |
Articolul urmator |
367 0 |
SM ISO690:2012 DASANU, Constantin A., ALVAREZ-ARGOTE, Juliana, LIMONADI, Farhad M., CODREANU, Ion. Bevacizumab in refractory higher-grade and atypical meningioma: the current state of affairs. In: Expert Opinion on Biological Therapy, 2019, nr. 2(19), pp. 99-104. ISSN 1471-2598. DOI: https://doi.org/10.1080/14712598.2019.1559292 |
EXPORT metadate: Google Scholar Crossref CERIF DataCite Dublin Core |
Expert Opinion on Biological Therapy | |
Numărul 2(19) / 2019 / ISSN 1471-2598 /ISSNe 1744-7682 | |
|
|
DOI:https://doi.org/10.1080/14712598.2019.1559292 | |
Pag. 99-104 | |
Rezumat | |
Introduction: Historically, systemic agents had shown limited efficacy in meningioma, at the expense of significant pharmacologic and/or financial toxicity. As meningiomas are highly vascularized, they might derive benefit from antiangiogenic therapy. Areas covered: This review summarizes the literature regarding bevacizumab pharmacology, safety and efficacy in patients with refractory meningioma. We have searched PubMed/Medline database for pertinent articles published from inception to 1 September 2018. Expert commentary: Results of two prospective phase II trials, supported by several retrospective cohorts, suggest a clinical benefit for the vascular endothelial growth factor inhibitor bevacizumab in meningiomas refractory to surgery and radiation therapy. This agent has a tolerable toxicity profile and seems more effective in higher-grade histologies and atypical meningioma, although responses in low-grade meningiomas have also been documented. Our conclusions are restricted due to a small size and lack of control in the prospective trials as well as the retrospective design of other studies. Further study of bevacizumab in refractory higher-grade meningiomas seems warranted. |
|
Cuvinte-cheie angiogenesis, Bevacizumab, Meningioma, refractory, vascular endothelial growth factor/receptor (VEGF/R) |
|
|